Prasad R, Rehman A, Rehman L, et al. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood. 2025;145(8):823-839. Free

On page 823, the byline omits an author, Frederick L. Locke. The byline and author affiliations should read as follows:

Rishika Prasad,^1,∗ Abdur Rehman,^2,∗ Lubna Rehman,^2,∗ Faezeh Darbaniyan,^2,∗ Viktoria Blumenberg,^3-5,∗ Maria-Luisa Schubert,^6,∗ Uria Mor,⁷ Eli Zamir,⁸ Sabine Schmidt,⁸ Tomo Hayase,¹ Chia-Chi Chang,¹ Lauren McDaniel,¹ Ivonne Flores,¹ Paolo Strati,² Ranjit Nair,² Dai Chihara,² Luis E. Fayad,² Sairah Ahmed,² Swaminathan P. Iyer,² Michael Wang,² Preetesh Jain,² Loretta J. Nastoupil,² Jason Westin,² Reetakshi Arora,² Joel Turner,⁹ Fareed Khawaja,¹⁰ Ranran Wu,¹¹ Jennifer B. Dennison,¹¹ Meghan Menges,⁹ Melanie Hidalgo-Vargas,⁹ Kayla Reid,⁹ Frederick L. Locke,⁹ Marco L. Davila,¹² Peter Dreger,⁶ Felix Korell,⁶ Anita Schmitt,⁶ Mark R. Tanner,¹³ Richard E. Champlin,¹³ Christopher R. Flowers,² Elizabeth J. Shpall,¹³ Samir Hanash,¹¹ Sattva S. Neelapu,² Michael Schmitt,⁶ Marion Subklewe,^3-5 Johannes Francois-Fahrmann,¹¹ C. K. Stein-Thoeringer,^14,15 Eran Elinav,^7,8 Michael D. Jain,⁹ Eiko Hayase,¹ Robert R. Jenq,^1,13 and Neeraj Y. Saini^2,13

¹Department of Genomic Medicine and ²Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; ³Department of Medicine III, Ludwig Maximilian University of Munich University Hospital, Ludwig Maximilian University of Munich, Munich, Germany; ⁴Laboratory for Translational Cancer Immunology, Ludwig Maximilian University of Munich Gene Center, Ludwig Maximilian University of Munich, Munich, Germany; ⁵German Cancer Consortium and Bavarian Center for Cancer Research, Partner Site Munich, Munich, Germany; ⁶Department of Hematology, Oncology, and Rheumatology, University Clinic Heidelberg, Heidelberg, Germany; ⁷Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel; ⁸Division of Microbiome and Cancer, German Cancer Consortium, Heidelberg, Germany; ⁹Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL; ¹⁰Department of Infectious Diseases, Infection Control and Employee Health and ¹¹Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX; ¹²Department of Stem Cell Transplantation and Cellular Therapy, Roswell Cancer Institute, Buffalo, NY; ¹³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; ¹⁴Department of Internal Medicine I, University Clinic Tübingen, Tübingen, Germany; and ¹⁵M3 Research Institute, Faculty of Medicine, University of Tübingen, Tübingen, Germany

On pages 837-838, the authorship contribution statement should include the information that Frederick L. Locke supervised patient recruitment and data and biospecimen collection, and the conflict-of-interest disclosure should include the information that Frederick L. Locke received research funding from 2SeventyBio, Allogene, BMS, Novartis, Incyte, Kite Pharma, the Leukemia and Lymphoma Society (Scholar in Clinical Research, principal investigator: Frederick L. Locke), the Mark Foundation, and the National Cancer Institute (NCI; grant R01CA244328); has patents held by his institution in his name (unlicensed) in the field of CAR T-cell therapy; has served as a compensated educational or scientific consultant for A2, Adaptive Biotechnologies, Adaptimmune, Allogene, Amgen, AstraZeneca, Bluebird Bio, BMS, Calibr, Caribou, EcoR1 Capital, the Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, Poseida, Aptitude Health, the American Society of Hematology, the American Society for Transplantation and Cellular Therapy, Clinical Care Options Oncology, and the Society for Immunotherapy of Cancer; and serves as a cochair of the data and safety monitoring board for the National Cancer Institute (NCI), Center for Cancer Research (CCR) Office of Sponsor and Regulatory Oversight (OSRO) Safety Oversight Committees Cell Therapy.